FibroGen
Sean Healy is an accomplished quality assurance executive with extensive experience in the pharmaceutical and biotechnology sectors. Currently serving as VP Quality at FibroGen, Inc. since May 2016 and as VP of Quality at Cellerant Therapeutics since August 2011, Sean Healy has held various leadership roles including Executive Director QA and Sr. Director/Head of Quality. Previous positions include Director of Quality Operations at Tercica, Director of QA and Associate Director Quality at Theravance, and Manager of Contract Operations QA at Pfizer. Sean Healy began a career in the industry as a Scientist at Block Drug Company. Educationally, Sean Healy earned a Ph.D. in Physical/Analytical Chemistry from Seton Hall University.
This person is not in the org chart
This person is not in any teams
FibroGen
FibroGen, Inc. is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the Company's most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD), and is entering Phase III development for anemia in lower risk myelodysplastic syndromes (MDS). The Company has developed Pamrevlumab. Pamrevlumab is a proprietary therapeutic antibody to inhibit the activity of connective tissue growth factor (CTGF), a common factor in chronic fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure.